Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.22.2.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Total revenue $ 426 $ 239 $ 796 $ 441
Costs of revenue 89 190 235 324
Gross profit 337 49 561 117
Operating expenses:        
Research and development 1,523 1,603 4,651 4,402
General and administrative 1,069 933 2,918 2,791
Sales and marketing 291 338 1,023 953
Grant and contract expenses 247 423
Total operating expenses 3,130 2,874 9,015 8,146
Loss from operations (2,793) (2,825) (8,454) (8,029)
Other income (expenses):        
Interest expense (4) (1) (12) (2)
Interest income 5 3 8 99
Loss on disposal of assets (1)
Change in fair value of derivative liabilities 60 481 208 225
Forgiveness of PPP loan 391
Other income, net 8 (1) 170 141
Total other income (expense), net 69 482 373 854
Net loss before income taxes (2,724) (2,343) (8,081) (7,175)
Provision for income taxes
Net loss $ (2,724) $ (2,343) $ (8,081) $ (7,175)
Net loss per share – basic and diluted        
Basic – net loss $ (0.11) $ (0.09) $ (0.33) $ (0.29)
Diluted –net loss $ (0.11) $ (0.11) $ (0.33) $ (0.29)
Weighted average common shares outstanding:        
Basic 24,724,792 24,703,156 24,717,904 24,686,533
Diluted 25,086,999 25,069,343 25,084,092 25,097,138
Product [Member]        
Total revenue $ 173 $ 239 $ 354 $ 441
Grant and Contract [Member]        
Total revenue $ 253 $ 442